News coverage about Bellerophon Therapeutics (NASDAQ:BLPH) has been trending somewhat positive this week, Accern Sentiment reports. Accern identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bellerophon Therapeutics earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 46.0846263942279 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media headlines that may have effected Accern Sentiment’s analysis:

A number of research firms recently commented on BLPH. Zacks Investment Research upgraded Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a report on Monday, August 14th. ValuEngine cut Bellerophon Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, June 10th.

Bellerophon Therapeutics (NASDAQ BLPH) traded up 2.73% during trading on Friday, reaching $1.13. The company had a trading volume of 362,407 shares. The company has a 50-day moving average price of $1.26 and a 200 day moving average price of $1.35. Bellerophon Therapeutics has a one year low of $0.43 and a one year high of $1.98. The company’s market capitalization is $40.13 million.

Bellerophon Therapeutics (NASDAQ:BLPH) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.03. Analysts expect that Bellerophon Therapeutics will post ($1.12) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Bellerophon Therapeutics (BLPH) Given Media Impact Rating of 0.13” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/01/bellerophon-therapeutics-blph-given-media-impact-rating-of-0-13.html.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Insider Buying and Selling by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)

Receive News & Stock Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related stocks with our FREE daily email newsletter.